Skip to main content

COVID 19 Updates from RheumNow

What Worries You, Masters You (7.1.2022)

Dr. Jack Cush reviews recent news, regulatory and guideline updates from the past week on RheumNow.com.  Studies on methotrexate use, COVID vaccination, Supplements and vitamins, and arthrocentesis despite anticoagulation are discussed.

Two Week Methotrexate Hold with COVID-19 Vaccination

A cohort study of rheumatoid arthritis (RA) patients evaluated immunogenicity of COVID vaccination with and without holding methotrexate (MTX) for and 2-weeks and showed better immunogenicity, but more RA flares with the second MTX withdrawal. 

COVID-19 Death is Dependent on Age and Type I IFN Autoantibodies

A study in PNAS of has shown that autoantibodies against type I interferons (IFNs) are strong predictors of death from COVID-19. This adds to the evidence that evidence preexisting autoantibodies neutralizing IFNs are strong determinants of life-threatening COVID-19 pneumonia.

What Happened to Kawasaki Disease During COVID-19?

During the COVID-19 pandemic, a new COVID-related syndrome in children, the "Multisystem inflammatory syndrome in children" (MIS), was described as being similar to but distinctly different than childhood

Spondyloarthritis and COVID-19

COVID-19 and our rheumatic diseases remains a hot topic. With the availability of vaccines and new therapeutics, many of our patients are now fully vaccinated and boosted.

Recommendations – Good & Bad (5.27.2022)

Dr. Jack Cush reviews the news, regulatory updates and journal reports from the past week on RheumNow.com. This week gout worries, mortality risks, measuring anti-drug antibodies and a better way in lupus?

Increasing Corticosteroid Use in Non-Hospitalized COVID-19

JAMA reports that despite NIH recommendations (that corticosteroids only be used in hospitalized COVID-19 patients), nonhospitalized COVID infected patients were oftent prescribed systemic corticosteroids.

Long COVID Manifestations

MMWR

The acute consequences of a SARS-CoV-2 infection may be bothersome or devastating, but the long-term consequences may lead to so-called "long COVID" syndrome.  Long COVID appears to affect up to 20% of those who survive COVID-19 infection. 

The Inflammation Reflex (5.20.2022)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, neuroimmunology leading to therapy, the cold shoulder approach and Regulatory updates from the FDA.

Methotrexate Monitoring (5.13.2022)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Bad news for digitial ulcers in Systemic sclerosis, Readmissions in Lupus and Thrombocytopenia in APL patients.

$30 Billion and Counting (4.29.2022)

Dr. Jack Cush reviews the news and journal reports and takes viewer questions this week.

Social

COVID-19 Death is Dependent on Age and Type I IFN Autoantibodies https://t.co/WrWujgHoA4 https://t.co/NTwUeXHYKr
Dr. John Cush @RheumNow ( View Tweet )
1 week ago
COVID-19 hospitalization among Medicare diabled was ~50% higher (3,148/100k) than age matched pop. , and hospitalization rates increased with age in both groups. Among the disabled, American Indian or Alaska Natives had highest rate https://t.co/Xa4NlalHdf https://t.co/dP0c3ajQAW
Dr. John Cush @RheumNow ( View Tweet )
2 weeks ago
Review on reactive arthritis & COVID: 22 articles , 25 pts (14M:11F), age 45 yrs. Oligoarthritis was most common. Onset (COVID to arthritis) was 6-48 days. Steroids in 13, 2 w/ SSZ, Sxs improved 22/25, mean resolution was 16 +/- 57 days https://t.co/0YABcjz9Gk https://t.co/W5Vnn1NjkD
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 1 day ago
Spondyloarthritis and COVID-19 With the availability of vaccines and new therapeutics, many of our patients are fully vaccinated. We know this can limit their chances of severe COVID all while allowing their rheumatic disease to be treated. #EULAR2022 https://t.co/PmQNKYg1Ao https://t.co/N4DJVYJqrL
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 5 days ago
Biosimilars and COVID vaccines have made nocebo more pertinent than ever. How do we combat it? First line is good communication, and the foot soldiers are the right phrases. Language matters. #EULAR2022 @RheumNow https://t.co/U0Chv9ia1G
3 weeks 6 days ago
Rituximab/belimumab patients & COVID vaccination response: may have had average antibody response but there’s still the cellular response to consider too! Not as bad. Still caution++, but when ritux really needed we’ll find a way despite COVID from roundup #EULAR2022 @RheumNow https://t.co/zFr6QI9TOG
3 weeks 6 days ago
Sreekanth et al. 2 studies re holding MTX after both doses vs only 2nd dose of AZ COVID vaccine. Either holding strategy increased ab titres. Only holding 2nd non-inferior to holding both with decreased flares @RheumNow #EULAR2022 LB0003 https://t.co/aCOEdXp4ol https://t.co/XAZyBojryK
Richard Conway @RichardPAConway ( View Tweet )
3 weeks 6 days ago
#EULAR2022 LB0006 SAPHYR: P3 trial, 52 wk: Sarilumab in relapsing PMR Study terminated early due to COVID recruitment ⭐️Sustained remission: 28 vs 10%, primary endpt ⭐️HR of flare 0.56 on Sarilumab ⭐️Less steroid usage, glucocorticoid tox score @Rheumnow https://t.co/5PP1YP7YtU
3 weeks 6 days ago
#LB0006 #EULAR2022 Therapy for relapsing polymyalgia rheumatica. 118/280 recruited re:COVID impact. Phase 3 RCT of Sarilumab+14Wk Steroid taper showed more pts had sustained remission at Wk52 vs PBO+52Wk Steroid Taper(28% vs 10%) even if CRP excluded. PRO improved too! @RheumNow https://t.co/P11iXIAfGn
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
3 weeks 6 days ago
#EULAR2022 LB003: W/d MTX w COVID vax MIVAC 1: hold MTX both vax vs continuing MIVAC 2: hold after 2nd dose only vs continuing ⭐️MTX hold: improved Ab titers, no diff in MIVAC1/2 ⭐️Higher reported flare for holding with both doses (36%) vs just 2nd dose (12%) @Rheumnow
3 weeks 6 days ago
×